-
公开(公告)号：US09012469B2
公开(公告)日：2015-04-21
申请号：US13823953
申请日：2011-09-29
Applicant: Bengt Leonard Åslund , Carl-Johan Aurell , Martin Hans Bohlin , Eric Thomas Healy , David Richard Jensen , David Thomas Jonaitis , Stephan Parent , Tesfai Sebhatu , Bo Ingvar Ymén
Inventor： Bengt Leonard Åslund , Carl-Johan Aurell , Martin Hans Bohlin , Eric Thomas Healy , David Richard Jensen , David Thomas Jonaitis , Stephan Parent , Tesfai Sebhatu , Bo Ingvar Ymén
IPC: A61K31/485 , C07D489/04 , A61K47/48 , C07C51/41 , C07C55/07
CPC classification number: A61K47/48215 , A61K47/60 , C07B2200/13 , C07C51/41 , C07C55/07 , C07D489/04
Abstract: Naloxol-polyethlyene glycol conjugates of the formula: are provided in oxalate or phosphate salt forms including crystalline forms. Methods of preparing the salt forms and pharmaceutical compositions comprising the salt forms are also provided.
Abstract translation: 下式的纳洛酮 - 聚乙二醇共轭物以草酸盐或磷酸盐形式提供，包括结晶形式。 还提供了制备盐形式的方法和包含盐形式的药物组合物。
-
公开(公告)号：US20150038524A1
公开(公告)日：2015-02-05
申请号：US13823953
申请日：2011-09-29
Applicant: Bengt Leonard Aslund , Carl-Johan Aurell , Martin Hans Bohlin , David Richard Jensen , David Thomas Jonaitis , Eric Thomas Healy , Bo Ingvar Ymén , Stephan Parent , Tesfai Sebhatu
Inventor： Bengt Leonard Aslund , Carl-Johan Aurell , Martin Hans Bohlin , David Richard Jensen , David Thomas Jonaitis , Eric Thomas Healy , Bo Ingvar Ymén , Stephan Parent , Tesfai Sebhatu
IPC: A61K47/48 , A61K31/485 , C07C55/07 , C07D489/04 , C07C51/41
CPC classification number: A61K47/48215 , A61K47/60 , C07B2200/13 , C07C51/41 , C07C55/07 , C07D489/04
Abstract: Naloxol-polyethylene glycol conjugates of the formula: are provided in oxalate or phosphate salt forms including crystalline forms. Methods of preparing the salt forms and pharmaceutical compositions comprising the salt forms are also provided.
Abstract translation: 下式的纳洛酮 - 聚乙二醇缀合物以草酸盐或磷酸盐形式提供，包括晶型。 还提供了制备盐形式的方法和包含盐形式的药物组合物。
-
3.发明申请Polymorphic forms of (S). -tetrahydrofuran-3-yl-3- (3- (3-methoxy-4- (oxazol-5-yl) pheny1) ureido) benzylcarbamate 失效（S）-1-四氢呋喃-3-基-3-（3-（3-甲氧基-4-（恶唑-5-基）苯基）脲基）苄基氨基甲酸酯的多晶型公开(公告)号：US20070281980A1
公开(公告)日：2007-12-06
申请号：US11429811
申请日：2006-05-08
Applicant: Todd Blythe , Alex Eberlin , Michael Hurrey , David Jonaitis , Philip Nyce , Stephan Parent , John Snoonian
Inventor： Todd Blythe , Alex Eberlin , Michael Hurrey , David Jonaitis , Philip Nyce , Stephan Parent , John Snoonian
IPC: A61K31/422 , C07D413/02
CPC classification number: C07D413/12
Abstract: The present invention relates to polymorphic forms of (S)-tetrahydrofuran-3-yl 3-(3-(3-methoxy-4-(oxazol-5-yl)phenyl)ureido)benzylcarbamate, processes therein, pharmaceutical compositions thereof, and uses therewith.
Abstract translation: 本发明涉及（S） - 四氢呋喃-3-基3-（3-（3-甲氧基-4-（恶唑-5-基）苯基）脲基）苄基氨基甲酸酯的多晶形式，其中的方法，其药物组合物和 与其一起使用。
-
公开(公告)号：US20070149457A1
公开(公告)日：2007-06-28
申请号：US11638047
申请日：2006-12-12
Applicant: Byron Rubin , David Jonaitis , Stephan Parent
Inventor： Byron Rubin , David Jonaitis , Stephan Parent
IPC: A61K38/31
Abstract: The present invention provides co-complexes of enterostatin that can display advantageous hygroscopicity, advantageous stability, or both. The co-complexes of enterostatin can be useful for the manufacture of an pharmaceutical product comprising enterostatin.
Abstract translation: 本发明提供了可显示有利的吸湿性，有利的稳定性或两者的肠抑素的共复合物。 肠抑素的共复合物可用于制造包含肠抑素的药物产品。
-
公开(公告)号：US20120165260A2
公开(公告)日：2012-06-28
申请号：US13041136
申请日：2011-03-04
Applicant: STEPHAN PARENT , STEVEN SCHOW
Inventor： STEPHAN PARENT , STEVEN SCHOW
CPC classification number: C07K5/0215 , A61K38/00
Abstract: Crystalline ezatiostat hydrochloride ansolvate form D is more stable and/or more soluble that various solvated crystalline polymorphic forms of ezatiostat hydrochloride.
Abstract translation: 盐酸环磷酰胺盐酸盐的各种溶剂化结晶多晶型形式的盐酸盐稳定剂D型更稳定和/或更易溶解。
-
Patent Agency Ranking
6.发明授权Polymorphic forms of (S)-1-tetrahydrofuran-3-yl-3-(3-(3-methoxy-4-(oxazol-5-yl)phenyl)ureido)benzylcarbamate 失效（S）-1-四氢呋喃-3-基-3-（3-（3-甲氧基-4-（恶唑-5-基）苯基）脲基）苄基氨基甲酸酯的多晶型公开(公告)号：US08153668B2
公开(公告)日：2012-04-10
申请号：US12555203
申请日：2009-09-08
Applicant: Todd Blythe , Alex Eberlin , Michael Hurrey , David Jonaitis , Philip Nyce , Stephan Parent , John Snoonian
Inventor： Todd Blythe , Alex Eberlin , Michael Hurrey , David Jonaitis , Philip Nyce , Stephan Parent , John Snoonian
IPC: A61K31/422
CPC classification number: C07D413/12
Abstract: The present invention relates to polymorphic forms of (S)-tetrahydrofuran-3-yl 3-(3-(3-methoxy-4-(oxazol-5-yl)phenyl)ureido)benzylcarbamate, processes therein, pharmaceutical compositions thereof, and uses therewith.
Abstract translation: 本发明涉及（S） - 四氢呋喃-3-基3-（3-（3-甲氧基-4-（恶唑-5-基）苯基）脲基）苄基氨基甲酸酯的多晶形式，其中的方法，其药物组合物和 与其一起使用。
-
7.发明申请公开(公告)号：US20070093504A1
公开(公告)日：2007-04-26
申请号：US11552134
申请日：2006-10-23
Applicant: Dennis Bennett , Stephan Parent , David Jonaitis
Inventor： Dennis Bennett , Stephan Parent , David Jonaitis
IPC: A61K31/495 , C07D241/04
CPC classification number: C07D295/26 , A61K31/496
Abstract: Salt forms of potent modulators of peroxisome proliferator activated receptors, pharmaceutical compositions comprising the same, and methods of treating disease using the same are disclosed.
Abstract translation: 公开了过氧化物酶体增殖物激活受体的有效调节剂的盐形式，包含其的药物组合物和使用其的治疗疾病的方法。
-
8.发明申请POLYMORPHIC FORMS OF (S)-1-TETRAHYDROFURAN-3-YL-3-(3-(3-METHOXY-4-(OXAZOL-5-YL)PHENYL)UREIDO)BENZYL CARBAMATE 失效（S）-1-四氢呋喃-3-基-3-（3-（3-甲氧基-4-（氧杂唑-5-基）苯基）脲基）乙酸苄酯的多晶型公开(公告)号：US20090324545A1
公开(公告)日：2009-12-31
申请号：US12555203
申请日：2009-09-08
Applicant: Todd Blythe , Alex Eberlin , Michael Hurrey , David Jonaitis , Philip Nyce , Stephan Parent , John Snoonian
Inventor： Todd Blythe , Alex Eberlin , Michael Hurrey , David Jonaitis , Philip Nyce , Stephan Parent , John Snoonian
IPC: C07D413/12 , A61K31/422 , A61K38/21 , A61K31/70 , A61P17/00 , A61P35/04 , A61P35/02 , A61P41/00 , A61P37/00 , A61P9/00 , A61P7/00 , A61P1/00 , A61P17/06 , A61P19/02
CPC classification number: C07D413/12
Abstract: The present invention relates to polymorphic forms of (S)-tetrahydrofuran-3-yl 3-(3-(3-methoxy-4-(oxazol-5-yl)phenyl)ureido)benzylcarbamate, processes therein, pharmaceutical compositions thereof, and uses therewith.
Abstract translation: 本发明涉及（S） - 四氢呋喃-3-基3-（3-（3-甲氧基-4-（恶唑-5-基）苯基）脲基）苄基氨基甲酸酯的多晶形式，其中的方法，其药物组合物和 与其一起使用。
-
9.发明授权Polymorphic forms of (S).-tetrahydrofuran-3-yl-3-(3-(3-methoxy-4-(oxazol-5-yl) phenyl) ureido) benzylcarbamate 失效（S）-1-四氢呋喃-3-基-3-（3-（3-甲氧基-4-（恶唑-5-基）苯基）脲基）苄基氨基甲酸酯的多晶型公开(公告)号：US07605270B2
公开(公告)日：2009-10-20
申请号：US11429811
申请日：2006-05-08
Applicant: Todd Blythe , Alex Eberlin , Michael Hurrey , David Jonaitis , Philip Nyce , Stephan Parent , John Snoonian
Inventor： Todd Blythe , Alex Eberlin , Michael Hurrey , David Jonaitis , Philip Nyce , Stephan Parent , John Snoonian
IPC: C07D263/32
CPC classification number: C07D413/12
Abstract: The present invention relates to polymorphic forms of (S)-tetrahydrofuran-3-yl 3-(3-(3-methoxy-4-(oxazol-5-yl)phenyl)ureido)benzylcarbamate (Compound 1): and pharmaceutical compositions thereof. The present invention also relates to processes to prepare compound 1 and pharmaceutical compositions thereof. Compound 1 is an IMPDH inhibitor useful in treating IMPDH-mediated diseases such as immune system related diseases, viral diseases, and cancers.
Abstract translation: 本发明涉及（S） - 四氢呋喃-3-基3-（3-（3-甲氧基-4-（恶唑-5-基）苯基）脲基）苄基氨基甲酸酯（化合物1）的多晶形式：及其药物组合物 。 本发明还涉及制备化合物1及其药物组合物的方法。 化合物1是可用于治疗IMPDH介导的疾病如免疫系统相关疾病，病毒性疾病和癌症的IMPDH抑制剂。
-
公开(公告)号：US20070299136A1
公开(公告)日：2007-12-27
申请号：US10598854
申请日：2005-04-22
Applicant: Douglas Johnson , Chris Murray , Stephan Parent , David Jonaitis
Inventor： Douglas Johnson , Chris Murray , Stephan Parent , David Jonaitis
CPC classification number: C07C235/38
Abstract: There are provided in accordance with the present invention crystalline forms A, B, C, F, G, I, J, P, and Q of efaproxiral sodium. Also provided is the amorphous form of efaproxiral sodium. Also provided are methods of forming the novel polymorphs and the amorphous form of efaproxiral sodium, therapeutic methods utilizing them and pharmaceutical dosage forms containing them.
Abstract translation: 根据本发明提供了依法甲磺酸钠的结晶形式A，B，C，F，G，I，J，P和Q。 还提供了非法形式的法非司酮钠。 还提供了形成新型多晶型物和非法形式的法非司酮钠的方法，利用它们的治疗方法和含有它们的药物剂型。
-
-
-
-
-
-
-
-
-
Search Results
11
records
(took 0.017 seconds)
